Literature DB >> 11500350

Diagnostic value of follow-up transbronchial lung biopsy after lung rejection.

C L Aboyoun1, M Tamm, P N Chhajed, P Hopkins, M A Malouf, S Rainer, A R Glanville.   

Abstract

Although transbronchial lung biopsy (TBBx) is widely acknowledged as the "gold standard" for diagnosis of acute rejection, controversy exists regarding the need to perform follow-up procedures. Over a 5-yr period, we performed 1,142 TBBx of which 173 were follow-up TBBx in 99 patients with pulmonary allograft rejection greater than or equal to International Society for Heart and Lung Transplantation (ISHLT) grade A(2) on initial TBBx. Rejection on the previous 173 TBBx was associated with lymphocytic bronchiolitis/bronchitis (LBB) > or = ISHLT grade B(2) in 82 patients and with cytomegalovirus (CMV) pneumonitis in 16 patients. Persistent rejection (> or = A(2)) was observed in 45 of 173 (26%) follow-up TBBx. Persistent B grade rejection (> or = B(2)) was present in 28 patients whereas new B grade rejection developed in 11 patients with > or = A(2) grade rejection. Rejection > or = B(2) was significantly (p < 0.05) associated with rejection > or = A(2). Fifteen follow-up TBBx showed new B grade rejection without signs of > or = A(2) rejection. A new diagnosis of CMV pneumonitis was made in 33 of 173 (19%). CMV pneumonitis occurred in 35 follow-up TBBx, four associated with > or = A(2) rejection and eight with > or = B(2) rejection. The overall incidence of bronchiolitis obliterans syndrome (BOS) in both groups was similar. Patients with persistent rejection on follow-up TBBx developed BOS at a median of 1.3 yr and median of 2.0 yr (p = not significant [NS]) posttransplantation. The practice of follow-up TBBx after rejection within 2 yr posttransplant is clinically useful as it provides valuable diagnostic information.

Entities:  

Mesh:

Year:  2001        PMID: 11500350     DOI: 10.1164/ajrccm.164.3.2011152

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

Review 1.  Acute rejection.

Authors:  Mark Benzimra; Greg L Calligaro; Allan R Glanville
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  [Heart and combined heart-lung transplantation. Indications, chances and risks].

Authors:  T Puehler; S Ensminger; U Schulz; U Fuchs; K Tigges-Limmer; J Börgermann; M Morshuis; K Hakim; O Oldenburg; J Niedermeyer; A Renner; J Gummert
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

Review 3.  Detection, classification, and management of rejection after lung transplantation.

Authors:  Amit D Parulekar; Christina C Kao
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 4.  The utility of bronchoscopy in immunocompromised patients: a review.

Authors:  Christopher Morton; Jonathan Puchalski
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

Review 5.  Heart-lung transplantation: pediatric indications and outcomes.

Authors:  Jonathan E Spahr; Shawn C West
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

Review 6.  Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis.

Authors:  Jean-François Cordier
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

7.  Prophylactic epinephrine for the prevention of transbronchial lung biopsy-related bleeding in lung transplant recipients (PROPHET) study: a protocol for a multicentre randomised, double-blind, placebo-controlled trial.

Authors:  Or Kalchiem-Dekel; Aldo Iacono; Edward M Pickering; Ashutosh Sachdeva; Nirav G Shah; Mark Sperry; Bich-Chieu Tran; Robert M Reed
Journal:  BMJ Open       Date:  2019-03-23       Impact factor: 2.692

Review 8.  Surveillance for acute cellular rejection after lung transplantation.

Authors:  Mark Greer; Christopher Werlein; Danny Jonigk
Journal:  Ann Transl Med       Date:  2020-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.